CHIKV VLP vaccine

BIOLOGICAL2 trials

Sponsors

Bavarian Nordic

Conditions

Chikungunya Virus

Phase 3

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

RecruitingNCT07003984

Bavarian NordicChikungunya Virus

Start: 2025-06-05End: 2028-12-01Target: 720Updated: 2026-03-24

An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults

RecruitingNCT07467707

Bavarian NordicChikungunya Virus

Start: 2026-05-26End: 2030-05-01Target: 6144Updated: 2026-06-29